Navigation Links
Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Date:4/25/2008

NEW YORK, April 25 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Institutional Review Board (IRB) of the University of Maryland Medical Center (UMMC) has approved UMMC's participation in the Phase III study of the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan to treat inoperable metastatic melanoma in the liver. The pivotal, Phase III study is being led by the National Cancer Institute (NCI), which previously approved the study's expansion to a multi-center trial.

UMMC has also entered into a clinical research agreement with Delcath enabling the hospital to immediately begin recruiting and treating patients. Richard Alexander, M.D., Professor of Surgery and Chief of Urology at the University of Maryland will serve as Principal Investigator of the study at this new center. Dr. Alexander, a recognized leader in the field of regional cancer therapy, was previously Deputy Director of the NCI's Center for Cancer Research, and Principal Investigator of the Phase I study that was Fast Tracked to this current Phase III study.

"The diagnosis of liver metastases results in a very poor prognosis for the patient," commented Dr. Alexander. "The Delcath System may represent an effective, minimally toxic means of restoring liver health and improving patient outcome. UMMC is committed to remaining at the forefront of cancer research and treatment. We look forward to participating in this NCI-led pivotal study and to understanding how this system may benefit patients."

"Expanding this Phase III study to premier oncology centers such as UMMC remains a top priority for the Company, as it allows the Delcath System to
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/dl9gbg/admetoxicology ) ... - Global Strategic Business Report" report to their ... for ADME-Toxicology Testing in US$ Million by the following ... The report provides separate comprehensive analytics for ... Japan , Europe , ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/vrd3bd/mammography ) has announced ... Strategic Business Report" report to their offering. ... Equipment in US$ Thousands by the following Product Segments: ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
Breaking Medicine Technology:Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... Inc. (Nasdaq: TRBN ) today announced financial results ... 30, 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , ... , Revenue for the third quarter and nine ... $12.8 million, respectively, compared with $3.8 million and $12.2 ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at ... on Wednesday, November 11, 2009 at 10:00 a.m. PT / ... finance and chief financial officer at Amylin Pharmaceuticals, will be ... presentation will be webcast and a recording will be made ...
Cached Medicine Technology:Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 2Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 3Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 4Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 5Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 6Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 7
(Date:4/17/2015)... 18, 2015 Rosetta Radiology is proud ... out their list of diagnostic imaging services. This solidifies ... on the Upper East Side of Manhattan. , The ... capacity. The addition of PET-CT, combined with Rosetta’s state ... ability to work with patients through several stages of ...
(Date:4/17/2015)... 17, 2015 Alcohol and Violence , ... notes that drinking and driving has been the focus ... same time, the link between alcohol and crime received ... and violence and sexual assault, and their relationship to ... NCADD, 5.3 million adults in America were drinking alcohol ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 From the day ... ago, the Texas non-profit organization has empowered young people to ... effort to bring fresh water and the Gospel to ... Liberty University. Between March 17 and 27, students, faculty and ... 7,000 Liberians with fresh water and the Good News of ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 At ... Entertainment’s EcoLuxe Lounge and the “Salute to the Oscars” ... luxurious Beverly Hilton Hotel, overlooking the impressive Los Angeles ... were organized by Debbie Durkin, LA’s leading producer of ... Showcasing many of the world’s premier providers of eco-friendly ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2
... Calif., Feb. 12 The Centers for Disease ... heart disease is America,s leading cause of death. ... a new heart-related coronary attack, and about 470,000 ... American Heart Month, thousands of people nationwide focus ...
... West Pharmaceutical Services, Inc. (NYSE: WST ... quarter financial results before the market opens on Thursday, ... call to discuss the results and business expectations at ... please dial (888)790-3758 or (210)839-8398. The passcode is WST.A ...
... results -LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. ... that it will host a conference call on Thursday, ... fourth quarter 2008 financial results. Labopharm will report its ... approximately 7:00 a.m. the same day. , To access ...
... Health Coordinates North Benin Screening , ... Cotonou, Benin, ... hospital ship, the Africa Mercy, docked in Cotounou, Benin , ... nation,s Ministry of Health. , , , , ,The hospital ...
... referred to as ,male menopause, may not be a ... depression, it is estimated that four out of five ... Since 1999, re NEW MAN (renewman.com) has been renowned ... self administered testosterone and HGH (human growth hormone) treatments. ...
... Portola to Receive $75 Million Upfront Cash ... Plus Royalties on Future Sales --SOUTH SAN ... Inc., a privately-held biopharmaceutical company developing innovative ... disease, inflammatory disease and cancer, today announced ...
Cached Medicine News:Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET) 2Health News:Mercy Ship Arrives in Benin 2Health News:Mercy Ship Arrives in Benin 3Health News:Male Hormone Replacement Therapy Optimism for 2009 2Health News:Male Hormone Replacement Therapy Optimism for 2009 3Health News:Male Hormone Replacement Therapy Optimism for 2009 4Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 2Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 3
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: